George A. Scangos

President & Chief Executive Officer at Vir Biotechnology, Inc.

George A. Scangos

George A. Scangos

President & Chief Executive Officer at Vir Biotechnology, Inc.

Overview
Career Highlights

Vir Biotechnology, Inc.
Biogen, Inc.
Exelixis, Inc.

RelSci Relationships

3426

Number of Boards

24

Birthday

1949

Age

72

Number of Awards

4

Relationships
RelSci Relationships are individuals George A. Scangos likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Exelixis, Inc.

Relationship likelihood: Strong

Venture Partner at ARCH Venture Partners

Relationship likelihood: Strong

Co-Founder at Vir Biotechnology, Inc.

Relationship likelihood: Strong

President & Secretary at Tomegavax, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Exelixis, Inc.

Relationship likelihood: Strong

Benefit Plan Administrator at White Cube Management LLC

Relationship likelihood: Strong

Editorial Advisor at Nature Biotechnology

Relationship likelihood: Strong

Co-Founder at Translate Bio, Inc.

Relationship likelihood: Strong

Director at Molecular Partners AG

Relationship likelihood: Strong

Chief Executive Officer at GRAIL, Inc.

Relationship likelihood: Strong

Paths to George A. Scangos
Potential Connections via
Relationship Science
You
George A. Scangos
President & Chief Executive Officer at Vir Biotechnology, Inc.
Education
Ph.D. in Microbiology
Class of 1977

UMass Amherst, the flagship campus of the University of Massachusetts system, sits on nearly 1,450-acres in the scenic Pioneer Valley of Western Massachusetts, 90 miles from Boston and 175 miles from New York City. The campus provides a rich cultural environment in a rural setting close to major urban centers.

B.A. in Biology

Cornell is a privately endowed research university and a partner of the State University of New York. As the federal land-grant institution in New York State, they have a responsibility—unique within the Ivy League—to make contributions in all fields of knowledge in a manner that prioritizes public engagement to help improve the quality of life in our state, the nation, the world.

Career History
President & Chief Executive Officer
2017 - Current

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Adjunct Professor, Biology
Current

The Krieger School of Arts and Sciences is devoted to discovery that creates new knowledge and solutions that better the world. The world-renowned faculty teach and engage in interdisciplinary and collaborative scholarship across the arts and humanities, the social sciences, and the natural sciences. The well-rounded and diverse students pursue a liberal arts education that leverages the qualities of a major research university. They explore their academic interests through a flexible curriculum and faculty-mentored, hands-on research projects utilizing critical inquiry. Their accomplished graduates possess the skills, curiosity, and knowledge to pursue satisfying and impactful lives of leadership and service in today’s global arena.

Chief Executive Officer & Director
2010 - 2016

Biogen has some of the world’s best neurologists and neuroscientists. They engage with physicians and scientific leaders around the world with the aim to further medical research. Their focus on neuroscience, their deep scientific expertise and courage to take risks makes them leaders in the research and development of medicines to transform neuroscience to benefit society. Their technology and engineering capabilities create novel ways to seamlessly transition products from development to manufacturing with the intent of bringing their high-quality medicines to market faster. They respect the contributions of health care providers caring for people living with neurological diseases. They honor the important role of caregivers, families and friends who care about them.

Boards & Committees
Non-Executive Chairman, Board of Directors
2003 - 2010

Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ.

Director
2000 - 2005

Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. At Onyx, we are grounded in three leadership hallmarks that guide how we manage our business and build value for patients and shareholders: innovation, patient-centeredness and stewardship.

Chairman, Board of Directors
2009 - Prior

CHI was founded in 1993 as an independent 501(c)(6) organization devoted to researching and advocating policy to forward the interests of California’s biomedical community.

Director
2006 - 2010

Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY.

Director
Prior

BayBio brings together the collective strength and experience of the world’s most innovative and productive life science cluster, helping companies grow, connect and advocate to solve some of humanity’s most pressing challenges. BayBio provides comprehensive support and solutions tailored to the unique needs of nearly 1000 Bay Area life science companies and institutions, delivering tangible value through group purchasing savings, capital access, government affairs & advocacy, networking and best-practice sharing. BayBio also supports the future of bioscience innovation through the BayBio Institute’s work in science education, career development and entrepreneurship.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$10K - $25K
2010

American Liver Foundation engages in facilitating, advocating and promoting education, support, and research for the prevention, treatment, and cure of liver disease. It educates patients, policymakers and the public and provides grants to early-career researchers to help find a cure for all liver diseases. The company was founded in 1976 and is headquartered in New York, NY.

Political Donations
$5,000
2016

Senator from Oregon

$5,000
2012

Former President of United States

$1,000
2012
Transactions
Details Hidden

Vir Biotechnology, Inc. raised money in a private placement transaction

Details Hidden

Vir Biotechnology, Inc. raised money in a private placement transaction

Details Hidden

Vir Biotechnology, Inc. raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.
Awards & Honors
Rank #151
2014
Chief Executive Magazine - Wealth Creators
Rank #9
2014
Fortune Magazine - Business Person of the Year
Rank #40
2014
Harvard Business Review - 100 Best-Performing CEOs in the World
Events
Speaker
New York City, NY
2012 Forbes Healthcare Summit

Attendee
New York City, NY
2012 Forbes Healthcare Summit

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by George A. Scangos. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of George A. Scangos's profile does not indicate a business or promotional relationship of any kind between RelSci and George A. Scangos.